A new research collaboration, option and license agreement has been signed between Pfizer and BioRap Technologies, the technology transfer company of the Rappaport Institute for Biomedical Research at the Technion – Israel Institute of Technology. The goal of the deal is to further develop a monoclonal antibody discovered by Prof. Nathan Karin and his team into potential new treatment options for a number of chronic autoimmune diseases. Pfizer has an exclusive option to obtain a license to the monoclonal antibody program. If the option is exercised, Pfizer will be responsible for further development and potential commercialization of any resulting product.


Please enter your comment!
Please enter your name here